IP Library › Granted Patent US 12,377,289
Granted Patent B2
US 12,377,289 · App. 18/035,612 · Granted Aug 5, 2025

Devices, systems, and methods for personalized dosimetry

Inventors: Larry A Pierce, II (Seattle, WA); Robert S. Miyaoka (Seattle, WA); Robert L Harrison (Seattle, WA)
Assignee: University of Washington
A61N5/1071A61B5/6805A61B6/032A61B6/037A61B6/0407A61B6/4266
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,289
App. No.
18/035,612
Granted
Aug 5, 2025
Kind
B2
Abstract

Various devices, systems, and methods for performing personalized dosimetry of a patient receiving a radiopharmaceutical are described. In an example method, anatomic data is generated by performing a computed tomography (CT) scan on the patient when they are lying down and wearing a garment. Based on the anatomic data, locations of organs of the patient are determined with respect to one or more fiducial markers integrated with the garment. Detectors for detecting photons from a radiopharmaceutical are placed on the garment based on locations of the organs. Subsequently, the patient may be administered a dose of the radiopharmaceutical. When the patient wears the garment, the detectors may detect photons released from the decaying radiopharmaceutical that is distributed in the organs. The radiation dosage to the organs may be determined based on the detected photons.

Claims (87)

1. A system, comprising:

a garment comprising:

a wrap configured to be worn by a subject when the subject is lying down;

one or more fiducial markers integrated with the wrap, the one or more fiducial markers comprising a material configured to attenuate x-rays;

detectors configured to be integrated with the wrap and to detect photons emitted by a radionuclide disposed inside of the subject; and

a first transceiver configured to transmit detection data indicative of the photons detected by the detectors;

a second transceiver configured to receive the detection data;

at least one processor; and

memory storing instructions that, when executed by the at least one processor, cause the at least one processor to perform operations comprising:

identifying anatomic data of the subject indicating locations of organs of the subject with respect to the one or more fiducial markers integrated with the wrap when the wrap is worn by the subject and the subject is lying down;

identifying positions of the detectors along the wrap;

determining, based on the detection data, the anatomic data, and the positions of the detectors along the wrap, radiation dosages to the organs; and

determining that the radiation dosages to the organs are below one or more thresholds; and

outputting a message indicating that the radiation dosages are below the one or more thresholds.

2. The system of claim 1 , wherein the garment comprises:

a shell comprising:

a surface contoured around a shape of a torso of the subject; and

at least one of polystyrene foam, fiberglass, or silicon; and

fabric configured to at least partially wrap around a torso of the subject.

3. The system of claim 1 , wherein determining, based on the detection data, the anatomic data, and the positions of the detectors along the wrap, the radiation dosages to the organs comprises:

generating, based on the position of the detectors relative to the organs, a systems matrix (P) comprising sensitivities of the detectors to the locations of the organs;

generating, based on the detection data, a data array (g) comprising counts of the photons detected by the detectors;

determine an dosage array (f) based on the following equation:

Pf=g , and

wherein f comprises a radiation distribution within the organs; and

determining the radiation dosages to the organs based on the radiation distribution within the organs.

4. The system of claim 1 , further comprising:

a positron emission tomography (PET)-computed tomography (CT) scanner configured to generate the anatomic data by performing a PET-CT scan on the subject when the wrap is worn by the subject, the subject is lying down, and the subject is dosed with a radiolabel, the radiolabel comprising a positron emitter and a first binding domain specifically binding a receptor, and

wherein a radiopharmaceutical comprises the radionuclide, a second binding domain specifically binding the receptor, and a chelator that connects the radionuclide to the second binding domain.

5. A method, comprising:

generating anatomic data by performing a computed tomography (CT) scan on a subject wearing a garment;

identifying, based on the anatomic data, location of organs of the subject with respect to one or more fiducial markers integrated with the garment by segmenting depictions of the organs in the CT scan;

determining, based on the location of the organs of the subject with respect to one or more fiducial markers of the garment, an optimal set of locations on the garment for detecting radiation from the organs of the subject;

outputting the set of locations on the garment;

receiving, from the garment, detection data indicating photons detected by detectors placed at the optimal set of locations on the garment when the subject is wearing the garment and has been dosed with a radiopharmaceutical targeting a receptor; and

determining, based on the detection data, radiation dosages to the organs.

6. The method of claim 5 , wherein the CT scan comprises a positron emission tomography-CT (PET-CT) scan performed when the subject is dosed with a positron emitter targeting the receptor.

7. The method of claim 5 , wherein the receptor comprises a somastatin receptor, a prostate-specific membrane antigen (PSMA) receptor, or a thyroid cancer cell, and

wherein the radiopharmaceutical comprises 177 Lu-DOTATATE, 68 Ga-PSMA, 177 Lu-PSMA, 131 I, or 124 I.

8. The method of claim 5 , wherein the organs comprise at least one of a kidney, a liver, a spleen, or bone marrow.

9. The method of claim 5 , wherein the subject is lying down when the subject is wearing the garment.

10. The method of claim 5 , wherein the set of optimal locations comprises 10 to 15 positions along the garment, and

wherein the detectors comprise 10 to 15 detectors.

11. The method of claim 5 , wherein determining, based on the detection data, radiation dosages to the organs comprises:

defining a linear operator that takes a set of x i vectors to a space of measurements in the detection data, wherein the x i vectors are indicative of the locations of the organs of the subject; and

determining the radiation dosages to the organs by performing an inversion of the linear operator.

12. The method of claim 5 , wherein determining, based on the detection data, radiation dosages to the organs comprises:

generating, based on positions of the detectors relative to the organs, a systems matrix (P) comprising sensitivities of the detectors to the locations of the organs;

generating a data array (g) comprising counts of the photons detected by the detectors;

determining an dosage array (f) based on the following equation:

Pf=g , and

wherein f comprises a radiation distributions within the organs; and

determining the radiation dosages to the organs based on the radiation distributions within the organs.

13. The method of claim 5 , further comprising:

determining, based on the anatomic data, locations of tumors of the subject with respect to the one or more fiducial markers,

wherein determining the optimal set of locations on the garment for detecting radiation from the organs of the subject is further based on the locations of the tumors of the subject.

14. The method of claim 5 , further comprising:

determining, based on the anatomic data, optimal fields-of-view for the detectors;

determining pinhole sizes corresponding to the optimal fields-of-view; and

outputting the pinhole sizes.

15. The method of claim 5 , wherein the detection data comprises:

first photon counts detected by the detectors at a first time; and

second photon counts detected by the detectors at a second time, and

wherein the method further comprises:

generating a photon count model based on a predetermined half-life of the radiopharmaceutical and at least one of the first photon counts or the second photon counts;

determining that a difference between third photon counts detected by the detectors at a third time and the photon count model is greater than a threshold amount; and

excluding the third photon counts from the detection data.

16. The method of claim 5 , the detection data being first detection data indicating photons detected by the detectors when the subject has a first dose of the radionuclide targeting the receptor, the radiation dosages being first radiation dosages, the method further comprising:

receiving, from the garment, second detection data indicating photons detected by the detectors when the subject is wearing the garment and has a second dose of the radiopharmaceutical targeting the receptor;

determining, based on the second detection data, second radiation dosages to the organs; and

determining total radiation dosages to the organs by adding the first radiation dosages and the second radiation dosages.

17. The method of claim 16 , further comprising:

receiving, from a care provider, an indication of threshold radiation dosages;

determining that the total radiation dosages are less than the threshold radiation dosages; and

outputting a message indicating that the total radiation dosages are less than the threshold radiation dosages.

18. The method of claim 16 , the anatomic data being first anatomic data, the locations of the organs being first locations of the organs, the method further comprising:

in response to receiving the first detection data, generating second anatomic data by performing a CT scan on the subject when the subject is wearing a garment

identifying, based on the second anatomic data, second locations of the organs of the subject with respect to one or more fiducial markers integrated with the garment,

wherein determining the second radiation dosages to the organs is further based on the second locations of the organs.

19. A garment, comprising:

a wrap configured to be worn by a subject when the subject is lying down, the wrap comprising fabric configured to at least partially wrap around a torso of the subject;

a shell comprising a surface contoured to a shape of the subject;

one or more fiducial markers integrated with the wrap, the one or more fiducial markers comprising a material configured to attenuate x-rays;

detectors integrated with the wrap and configured to detect photons emitted by a radionuclide;

one or more batteries configured to supply electrical power to the detectors; and

a transceiver configured to transmit data indicative of the photons to an external device.

20. The garment of claim 19 , wherein the shell comprises at least one of polystyrene foam, fiberglass, or silicon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2023
From: PIERCE, II, LARRY A.; MIYAOKA, ROBERT S.; HARRISON, ROBERT L
To: UNIVERSITY OF WASHINGTON
Reel/Frame 064515/0151 →
Continuity (2)
Provisional Application 63110780 · Nov 6, 2020
Related Publication 20240066322A1 · Feb 29, 2024
References Cited (82)
US 5803089A · Ferre et al. · 1998 [cited by applicant]
US 6381482B1 · Jayaraman et al. · 2002 [cited by applicant]
US 9002438B2 · Knowland et al. · 2015 [cited by applicant]
US 9314160B2 · Adler, Jr. et al. · 2016 [cited by applicant]
US 9939533B2 · Knowland et al. · 2018 [cited by applicant]
US 10029120B2 · Schulz et al. · 2018 [cited by applicant]
US 10852446B2 · Knowland et al. · 2020 [cited by applicant]
US 20030193032A1 · Marshall · 2003 [cited by applicant]
US 20040008810A1 · Nelson et al. · 2004 [cited by applicant]
US 20040236207A1 · Widener et al. · 2004 [cited by applicant]
US 20060027756A1 · Thomson et al. · 2006 [cited by applicant]
US 20070265230A1 · Rousso et al. · 2007 [cited by applicant]
US 20090145655A1 · Gladd et al. · 2009 [cited by applicant]
US 20100322854A1 · Low et al. · 2010 [cited by applicant]
US 20110208044A1 · Edwards et al. · 2011 [cited by applicant]
US 20120080602A1 · Garcia Diego et al. · 2012 [cited by applicant]
US 20120148132A1 · Couch et al. · 2012 [cited by applicant]
US 20130218001A1 · Uhlemann · 2013 [cited by applicant]
US 20140088401A1 · Cai et al. · 2014 [cited by applicant]
US 20140275939A1 · Mitteldorf · 2014 [cited by applicant]
US 20150247933A1 · McQuirter et al. · 2015 [cited by applicant]
US 20150301204A1 · Srivastava et al. · 2015 [cited by applicant]
US 20160103227A1 · Beddar et al. · 2016 [cited by applicant]
US 20160259063A1 · Lee et al. · 2016 [cited by applicant]
US 20170086763A1 · Verma et al. · 2017 [cited by applicant]
US 20170219720A1 · Cortesi et al. · 2017 [cited by applicant]
US 20170319155A1 · Rubenstein et al. · 2017 [cited by applicant]
US 20180092698A1 · Chopra · 2018 [cited by examiner]
US 20180193666A1 · Zhang et al. · 2018 [cited by applicant]
US 20190018148A1 · Ueno et al. · 2019 [cited by applicant]
US 20200206534A1 · Bzdusek · 2020 [cited by applicant]
CA 2941409A1 · 2014 [cited by applicant]
CN 109523586A · 2019 [cited by applicant]
EP 2967465A1 · 2016 [cited by applicant]
EP 3059612A1 · 2016 [cited by applicant]
EP 3432034 · 2019 [cited by applicant]
JP 2013183756A · 2013 [cited by applicant]
JP 6377574B2 · 2018 [cited by applicant]
JP 6434206B2 · 2018 [cited by applicant]
KR 20200015208A · 2020 [cited by applicant]
WO WO2017115340A1 · 2017 [cited by applicant]
WO WO2018022990A1 · 2018 [cited by applicant]
WO WO2019099551A1 · 2019 [cited by applicant]
WO WO2019217928A1 · 2019 [cited by applicant]
Calais and Turner, “Outpatient 1311-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety,” Clin Nucl Med, vol. 37, No. 8, pp. 732-737. [cited by applicant]
D'Arienzo, et al., “90Y PET-based dosimetry after selective internal radiotherapy treatments,” Nuclear Medicine Communications, vol. 33, No. 6, Jun. 2012, pp. 633-640. [cited by applicant]
Dewaraja, et al., “MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy,” Journal of Nuclear Medicine, vol. 53, No. 8, Aug. 1, 2012, 16 pages. [cited by applicant]
Fragogeorgi, et al., “Exploitation of SiPM technology for the developemnt of a Theranostic Imaging device,” Journal of Nuclear Medicine, vol. 56 (supplement 3) 1841, May 2015, 4 pages. [cited by applicant]
Frezza, et al., “Validation of irtGPUMCD, a GPU-based Monte Carlo internal dosimetry framework for radionuclide therapy,” Physica Medica, vol. 73, May 2020, pp. 95-104. [cited by applicant]
Goetz, et al., “Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent Lu-DOTATOC therapy”, Annals of Nuclear Medicine, Japanese Society of Nuclear Medicine, … [cited by applicant]
Gregory, et al., “Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy,” Phys. Med. Biol., vol. 64, 245013, 2019, 15 pages. [cited by applicant]
Grimes, “Patient-specific internal dose calculation techniques for clinical use in targeted radionuclide therapy,” 2013, 186 pages, obtained from https://open.library.ubc.ca/soa/cIRcle/collections/ubctheses/24/items/1.0… [cited by applicant]
Li, et al., “Fully-Depleted Silicon-on-Insulator Devices for Radiation Dosimetry in Cancer Therapy,” IEEE Transactions on Nuclear Science, vol. 61, No. 6, Dec. 2014, pp. 3443-3450. [cited by applicant]
Li, et al., “Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry—Technical Review,” Theranostics, vol. 7, No. 18, 2017, pp. 4551-4565. [cited by applicant]
Ma, et al., “Clinical implementation of a Monte Carlo treatment planning system,” Medical Physics, vol. 26, No. 10, Oct. 1999, pp. 2133-2143. [cited by applicant]
Malaroda, et al., “Multicellular Dosimetry in Voxel Geometry for Targeted Radionuclide Therapy,” Cancer Biotherapy & Radiopharmaceuticals, vol. 18, No. 3, 2003, 11 pages. [cited by applicant]
Mijnheer, et al., “In vivo dosimetry in external beam radiotherapy,” Med. Phys., vol. 40, No. 7, Jul. 2013, 19 pages. [cited by applicant]
Miyaoka, et al., “Wearable technology to enable personalization of Lu177-DOTATATE therapy for neuroendocrine tumor in patients”, Journal of Nuclear Medicine, Mar. 7, 2019, pp. 1-4. [cited by applicant]
Nascimenti, et al., “Application of Al2O3:C+fibre dosimeters for 290 MeV/n carbon therapeutic beam dosimetry,” Radiation Physics and Chemistry, vol. 115, Oct. 2015, pp. 75-80. [cited by applicant]
Nascimento, et al., “Medical dosimetry using a RL/OSL prototype,” Radiation Measurements, vol. 71, Dec. 2014, pp. 359-363. [cited by applicant]
Nuclear Medicine/Radiopharmaceuticals Market by Type & by Application : Global Forecasts to 2021. MarketsandMarkets [internet]. [cited Dec. 29, 2017] obtained from: https://www.marketsandmarkets.com/Market-Reports/radio… [cited by applicant]
Obenaus and Smith,. “Radiation Dose in Rodent Tissues During micro-CT Imaging”, Journal of X-Ray Science and Technology, vol. 12, No. 4, 2004, pp. 241-249. [cited by applicant]
Osovisky, et al., “SENTIRAD—An innovative personal radiation detector based on a scintillation detector and a silicon photomultiplier,” Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectr… [cited by applicant]
Park, et al., “Development of a Portable Device Based Wireless Medical Radiation Monitoring System,” Journal of Radiation Protection and Research, vol. vol. 39, No. 3, 2014, pp. 150-158. [cited by applicant]
Perks, 2008, “Medical dosimetry using optically stimulated luminescence dots and microStar readers”. 12. International congress of the International Radiation Protection Association (IRPA): Strengthening radiation prote… [cited by applicant]
Perrot, et al., “Internal dosimetry through Gate simulations of preclinical radiotherapy using a melanin-targeting ligand,” Phys. Med. Biol., vol. 59, 2014, pp. 2183-2198. [cited by applicant]
Petitguillaume, et al., “Three-Dimensional Personalized Monte Carlo Dosimetry in 90Y Resin Microspheres Therapy of Hepatic Metastases: Nontumoral Liver and Lungs Radiation Protection Considerations and Treatment Plannin… [cited by applicant]
Pourhomayoun, et al., “Accurate tumor localization and tracking in radiation therapy using wireless body sensor networks,” Comput Biol Med, vol. 50, Jul. 2014, pp. 41-48. [cited by applicant]
Prete, et al., “Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, No. 9, pp. 1490-15… [cited by applicant]
Prete, et al., “Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial,” Journal of Nuclear Medicine, vol. 58 (supplement 1… [cited by applicant]
Prideaux, et al., “Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry,” Journal of Nuclear Medicine, vol. 48, Issue 6, Jun… [cited by applicant]
Radioisotope Therapy [internet]. Peter MacCallum Cancer Centre. [cited Dec. 28, 2017] obtained from: https://www.petermac.org/patients-and-carers/treatments/radioisotope-therapy. [cited by applicant]
Radiotherapy: Technologies and Global Markets. BCC Research [internet]. [cited Dec. 29, 2017] obtained from: https://www.bccresearch.com/market-research/healthcare/radiotherapy-technologies-markets-report.html. [cited by applicant]
Sarrabayrouse and Siskos, “Radiation dose measurment using MOSFETs,” in IEEE Instrumentation & Measurement Magazine, vol. 1, No. 2, Jun. 1998, pp. 26-34. [cited by applicant]
Siegel, et al., “Cancer statistics,” CA Cancer J Clin, vol. 69, 2019, pp. 7-34. [cited by applicant]
Search Report for European Application No. 21890157.7, Dated Aug. 19, 2024, 9 pages. [cited by applicant]
Surveillance and Monitoring of Explosive, Chemical, Biological, and Nuclear Hazards. BCC Research [internet]. [cited Dec. 29, 2017] obtained from: https://www.bccresearch.com/market-research/safety-and-security/ecbn-haz… [cited by applicant]
Taylor, et al., “Proton tracking for medical imaging and dosimetry,” Journal of Instrumentation, vol. 10, 2018, 15 pages. [cited by applicant]
Williams and Raymond, “Fiber-optic-coupled RbMgF3:Eu2+ for remote radiation dosimetry,” Radiation Measurements, vol. 46, No. 10, Oct. 2011, pp. 1099-1102. [cited by applicant]
Williams, et al.,, “Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging,” Eur J Nucl Med Mol Imaging, vol. 43, No. 13, Aug. 25, 2016, pp. 2374-2380. [cited by applicant]
Woulfe, et al., “Optical fibre sensors: their role in in vivo dosimetry for prostate cancer radiotherapy,” Cancer Nanotechnol., vol. 7, No. 1, Oct. 18, 2016, 16 pages. [cited by applicant]
Search Report and Written Opinion for PCT Application No. PCT/US21/58270, mailed Feb. 4, 2022, 17 pages. [cited by applicant]
Cited By (1)
US 12,544,593